# Erasmus MC Cancer Institute

Source: https://onco.cc/institutions/erasmus-mc/  
OnCo record `erasmus-mc` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Rotterdam's OECI-accredited comprehensive cancer centre, where peptide receptor radionuclide therapy with lutetium-177 was pioneered and Europe's largest screening trials were led.

## Summary

Erasmus MC Cancer Institute unites the former Daniel den Hoed cancer clinic with the oncology departments of Erasmus University Medical Center and holds OECI comprehensive cancer centre accreditation. Its nuclear medicine group under Eric Krenning and Dik Kwekkeboom developed somatostatin-receptor imaging and then 177Lu-DOTATATE peptide receptor radionuclide therapy for neuroendocrine tumours, the treatment later validated in NETTER-1 and approved as Lutathera. Erasmus MC epidemiologists coordinated the European Randomized Study of Screening for Prostate Cancer and the NELSON lung screening trial, which showed a mortality reduction from low-dose CT screening. The institute co-founded the Holland Proton Therapy Centre in Delft with LUMC and TU Delft, and is a leading sarcoma, breast and neuro-oncology trial site under Stefan Sleijfer.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: Erasmus MC; Daniel den Hoed; Erasmus University Medical Center
- City: Rotterdam, NL
- Type: cancer-center
- Website: https://www.erasmusmc.nl/en/cancer-institute

## Sources

- Homepage: https://www.erasmusmc.nl/en/cancer-institute
- HollandPTC: https://www.hollandptc.nl

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/), [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [CT (computed tomography)](https://onco.cc/technologies/ct/), [PET/CT](https://onco.cc/technologies/pet-ct/), [Proton therapy](https://onco.cc/technologies/proton-therapy/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/), [SPECT & bone scan](https://onco.cc/technologies/spect/)
- targets: [Somatostatin receptor 2](https://onco.cc/targets/sstr2/)
- drugs: [Lutetium-177 dotatate](https://onco.cc/drugs/lutathera/)
- companies: [Novartis](https://onco.cc/companies/novartis/)
- institutions: [Leiden University Medical Center](https://onco.cc/institutions/lumc-leiden/), [Netherlands Cancer Institute (NKI-AvL)](https://onco.cc/institutions/nki/), [Organisation of European Cancer Institutes](https://onco.cc/institutions/oeci/)
- terms: [Stage shift](https://onco.cc/terms/stage-shift/), [Theranostics](https://onco.cc/terms/theranostics/)
- people: [H.M.W. Verheul](https://onco.cc/people/h-m-w-verheul/), [Harry J. de Koning](https://onco.cc/people/harry-de-koning/), [J. Jan B. van Lanschot](https://onco.cc/people/jan-van-lanschot/), [Martin J. van den Bent](https://onco.cc/people/martin-van-den-bent/), [Pieter Sonneveld](https://onco.cc/people/pieter-sonneveld/), [Remi A. Nout](https://onco.cc/people/remi-nout/), [Valery Lemmens](https://onco.cc/people/valery-lemmens/), [Winette T. A. van der Graaf](https://onco.cc/people/winette-van-der-graaf/)
- key papers: [Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial](https://onco.cc/key-papers/paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025/), [Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial](https://onco.cc/key-papers/paper-preopanc-preoperative-chemoradiotherapy-jco-2020/), [Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer (Dutch TME trial)](https://onco.cc/key-papers/paper-kapiteijn-dutch-tme-preoperative-radiotherapy-nejm-2001/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)
- trials: [PREOPANC-2](https://onco.cc/trials/preopanc-2/), [PREOPANC-3](https://onco.cc/trials/preopanc-3/), [TESLA RCT](https://onco.cc/trials/tesla-rct/)

---
JSON: https://onco.cc/api/v1/entities/erasmus-mc.json